California-based PinkDx is evaluating a simple vaginal swab test across 16 U.S. trial sites to detect endometrial cancer genetic signals in women with abnormal bleeding. The effort aims to address rising mortality rates from aggressive uterine cancers and reduce reliance on painful tissue biopsies, which fail to collect adequate samples in 30% of postmenopausal patients. Targeting 90% sensitivity in a 3,000-patient trial ending in 2026, PinkDx plans to offer the test commercially by mid-2027.
PinkDx test development and rollout timeline
- ▪The PinkDx swab test does not require U.S. Food and Drug Administration approval because PinkDx plans to process all diagnostic tests exclusively in its own laboratory.
- ▪California-based PinkDx is developing a clinician-administered vaginal swab test to detect endometrial cancer in women experiencing symptoms such as postmenopausal bleeding.
- ▪PinkDx expects to complete certification with the Centers for Medicare & Medicaid Services by early 2027, aiming to make the swab test available to patients by mid-2027.
How the PinkDx swab detects cancer
- ▪Dying uterine cancer cells shed genetic material carrying tumor fingerprints that travel to the vagina, where clinician swabs can collect the fragments for laboratory analysis.
- ▪In a preliminary study of 27 women undergoing hysterectomies, PinkDx detected tumor genetic signals in swab samples gathered directly at the vaginal opening.
PinkDx clinical trial targets
- ▪The PinkDx clinical trial aims for the vaginal swab test to detect at least 90% of endometrial cancers while correctly ruling out cancer in at least half of non-cancer cases.
- ▪An ongoing 16-site U.S. clinical study plans to enroll approximately 3,000 women and complete data collection by the end of 2026.
Limitations of biopsies and potential triage
- ▪National Cancer Institute official Dr. Nicolas Wentzensen stated that if performance targets hold, the PinkDx swab could serve as an initial triage step sparing half of patients from biopsies.
- ▪Standard endometrial cancer diagnostics rely on transvaginal ultrasounds to measure uterine lining thickness and tissue biopsies to identify cancerous or precancerous cells.
- ▪Endometrial tissue biopsies fail to collect sufficient tissue in approximately 30% of postmenopausal women due to thin uterine linings or narrow cervical openings.
Rising rates of endometrial cancer
- ▪Columbia University oncologist Dr. June Hou stated that endometrial cancer case counts are increasing annually at a rate higher than most other cancer types.
- ▪Endometrial cancer death rates and annual case diagnoses in the United States are increasing, driven in part by a rising prevalence of aggressive disease forms.
Story comments
Loading comments…